Fundraising Fox
TrialScope
Jersey City, US · Founded 2012 · Delaware corporation · 3 known investors
Find your way into TrialScope
Sign up to see every warm intro you have to TrialScope
- Paths you didn't know you had: your email and LinkedIn already hold routes to the TrialScope team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Founders & leadership
RA
Richard AguinaldoExecutive
EM
E. Michael ForgashExecutive
Board
MA
EJ
Eric JensenBoard director
JS
Joe StaufferBoard director
MB
JK
Jeffrey KozloffBoard director
JH
CS
Charles SaldariniBoard director
CN
Christopher NoeBoard director
JC
James C WalkerBoard director
Investors · 3
Edison Partnerslisted by Edison PartnersNashville · $5M – $25M
How we know: Edison Partners's portfolio page · Not right? Tell us
NewSpring CapitalreportedRadnor
How we know: funding news · Not right? Tell us
SV Health InvestorsreportedLondon · $1M – $20M
How we know: a partner's Signal profile · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$17.8M disclosed across 3 rounds · 2014–2018
▶$4MraisedSep 2018 · 5 investors · PharmaceuticalsRule 506(b)
▶$4MraisedSep 2018 · 5 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Jeffrey KozloffExecutive Officer, Director
- Marc LedermanDirector
- Matthew PatrasExecutive Officer
- James C. WalkerDirector
- Larry BerranDirector
- Michael KopelmanDirector
- Offering amount
- $4.5M
- Amount sold
- $4M
- First sale
- Sep 2018
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$3.6MraisedApr 2017 · 6 investors · PharmaceuticalsRule 506(b)
▶$3.6MraisedApr 2017 · 6 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Jeffrey KozloffDirector
- Michael A DiPianoDirector
- Mark HeinoldExecutive Officer, Director
- James HillDirector
- Charles SaldariniDirector
- Richard AguinaldoExecutive Officer
- Christopher NoeDirector
- James C WalkerDirector
- Offering amount
- $4M
- Amount sold
- $3.6M
- First sale
- Apr 2017
- Incorporated
- Corporation, Delaware, 2012
- Federal exemptions
- 06b
▶$10.2MraisedJun 2014 · 4 investors · PharmaceuticalsRule 506(b)
▶$10.2MraisedJun 2014 · 4 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Jim WalkerDirector
- Eric JensenDirector
- Joe StaufferDirector
- Michael BalmuthDirector
- Chris NoeDirector
- E. Michael ForgashExecutive Officer, Director
- Offering amount
- $10.2M
- Amount sold
- $10.2M
- First sale
- May 2014
- Incorporated
- Corporation, Delaware, 2012
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- Who are TrialScope's investors?
- TrialScope's investors include Edison Partners, NewSpring Capital, SV Health Investors.
- How much funding has TrialScope raised?
- TrialScope has disclosed $17.8M raised across 3 rounds.
- Where is TrialScope headquartered?
- TrialScope is headquartered in Jersey City, US.